Cargando…

Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update

Migraine and migraine variants are common, chronic and incapacitating neurovascular disorders with a high impact on health resources. There is an extensive evidence base provided by double-blind, placebo-controlled trials showing that topiramate is a safe, effective and well tolerated drug in the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmona, Sergio, Bruera, Osvaldo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731022/
https://www.ncbi.nlm.nih.gov/pubmed/19707282
_version_ 1782170921381920768
author Carmona, Sergio
Bruera, Osvaldo
author_facet Carmona, Sergio
Bruera, Osvaldo
author_sort Carmona, Sergio
collection PubMed
description Migraine and migraine variants are common, chronic and incapacitating neurovascular disorders with a high impact on health resources. There is an extensive evidence base provided by double-blind, placebo-controlled trials showing that topiramate is a safe, effective and well tolerated drug in the management of migraine and its variants, being especially promising in the management of migraine-vertigo syndrome. Models both in the US and the UK have also shown that it offers a cost benefit when direct and indirect costs are evaluated, by reducing work loss, improving quality of life and reducing the use of increasingly scarce health resources.
format Text
id pubmed-2731022
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27310222009-08-25 Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update Carmona, Sergio Bruera, Osvaldo Ther Clin Risk Manag Review Migraine and migraine variants are common, chronic and incapacitating neurovascular disorders with a high impact on health resources. There is an extensive evidence base provided by double-blind, placebo-controlled trials showing that topiramate is a safe, effective and well tolerated drug in the management of migraine and its variants, being especially promising in the management of migraine-vertigo syndrome. Models both in the US and the UK have also shown that it offers a cost benefit when direct and indirect costs are evaluated, by reducing work loss, improving quality of life and reducing the use of increasingly scarce health resources. Dove Medical Press 2009 2009-08-20 /pmc/articles/PMC2731022/ /pubmed/19707282 Text en © 2009 Carmona and Bruera, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Carmona, Sergio
Bruera, Osvaldo
Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
title Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
title_full Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
title_fullStr Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
title_full_unstemmed Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
title_short Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
title_sort prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731022/
https://www.ncbi.nlm.nih.gov/pubmed/19707282
work_keys_str_mv AT carmonasergio prophylatictreatmentofmigraineandmigraineclinicalvariantswithtopiramateanupdate
AT brueraosvaldo prophylatictreatmentofmigraineandmigraineclinicalvariantswithtopiramateanupdate